Executive Summary
Deltex Medical plc has developed and proven the CardioQTM haemodynamic monitor system, which it produces in the UK and markets around the world. The CardioQTM is used on patients undergoing surgery and on critically ill patients to monitor the heart's performance. By identifying and monitoring any problems early, the CardioQTM allows doctors to optimise the patient's haemodynamic status. Treating patients using the CardioQTM technology has been proven to help patients recover more fully and more quickly. Clinical studies show significant reductions in the length of hospital stay of up to 42%. Patients all around the world are benefiting from the enormous medical and economic benefits of Deltex Medical's technology - CardioQTMs have already been sold into over 30 countries. With the positive support of many of the world's leading medical experts in anaesthesia and critical care, Deltex Medical expects that haemodynamic optimisation will become a global standard medical practice. Deltex Medical intends to maintain and develop its market leading position and to build a substantial business as the wider medical community embraces the principles of haemodynamic optimisation.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
